Xtant Medical Holdings, Inc. (XTNT)
Stock Price Chart
Key Info
| Market Cap | 84.09M |
| Revenue (ttm) | 57.99M |
| Net Income (ttm) | -8.44M |
| Shares Out | 72.00M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 30, 2020 |
| Last Price | $1.17 |
| Previous Close | $1.36 |
| Change ($) | -0.19 |
| Change (%) | -14.12% |
| Day's Open | 1.26 |
| Day's Range | 1.12 - 1.31 |
| Day's Volume | 208,163 |
| 52-Week Range | 0.55 - 3.50 |
More Stats
| Market Cap | 84.09M |
| Enterprise Value | 160.63M |
| Earnings Date (est) | Mar 11, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 72.00M |
| Float | 70.76M |
| EPS (basic) | -0.65 |
| EPS (diluted) | -0.65 |
| FCF / Share | -0.30 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 583,839 |
| Short Ratio | 0.09 |
| Short % of Float | 0.83% |
| Beta | 1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 1.45 |
| PB Ratio | n/a |
| Revenue | 57.99M |
| Operating Income | -2.77M |
| Net Income | -8.44M |
| Free Cash Flow | -4.01M |
| Net Cash | -76.54M |
| Net Cash / Share | -1.06 |
| Gross Margin | 73.31% |
| Operating Margin | -4.78% |
| Profit Margin | -14.60% |
| FCF Margin | -6.91% |
| ROA | -2.86% |
| ROE | n/a |
| ROIC | -2.60% |
Analyst Forecasts
Analyst Consensus: Hold
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.68 | 72.20 | 82.61 | 90.00 | 59.35 | 35.33 | 33.07 | 32.98 | 30.15 | 15.42 |
| Revenue Growth | -10.42% | -12.6% | -8.21% | 51.66% | 67.97% | 6.83% | 0.28% | 9.39% | 95.55% | - |
| Gross Profit | 42.52 | 43.49 | 50.10 | 62.29 | 39.08 | 22.30 | 18.89 | 22.64 | 21.04 | 12.05 |
| Operating Income | -2.25 | -60.08 | -37.83 | -7.55 | -14.42 | -6.26 | -9.01 | -4.94 | -6.45 | -8.61 |
| Net Income | -8.22 | -70.10 | -52.41 | -19.49 | -2.17 | -10.51 | -12.69 | -7.71 | -3.01 | -19.47 |
| Shares Outstanding | 13.16 | 11.74 | 1.51 | 1.06 | 0.75 | 0.50 | 0.38 | 0.35 | 0.32 | 0.27 |
| Earnings Per Share | -0.63 | -5.97 | -34.76 | -18.46 | -2.88 | -21.12 | -33.60 | -21.60 | -9.60 | -73.20 |
| Operating Cash Flow | -0.41 | 1.21 | -0.54 | -14.41 | -9.10 | -7.32 | -4.89 | -10.79 | -7.36 | -8.37 |
| Capital Expenditures | -0.54 | -0.37 | -1.61 | -5.82 | -0.60 | -0.30 | -0.69 | -1.84 | -1.10 | -0.82 |
| Free Cash Flow | -0.96 | 0.85 | -2.15 | -20.22 | -9.70 | -7.62 | -5.59 | -12.63 | -8.46 | -9.19 |
| Cash & Equivalents | 5.24 | 6.80 | 2.86 | 2.58 | 6.37 | 4.47 | 3.05 | 4.93 | 0.75 | 0.33 |
| Total Debt | 78.54 | 78.57 | 139 | 131 | 111 | 20.99 | 16.68 | 14.92 | 8.39 | 2.47 |
| Net Cash / Debt | -73.30 | -71.77 | -136 | -128 | -104 | -16.53 | -13.63 | -10.00 | -7.64 | -2.14 |
| Assets | 43.16 | 46.42 | 106 | 144 | 141 | 27.95 | 28.88 | 34.50 | 23.17 | 15.76 |
| Liabilities | 87.36 | 90.19 | 164 | 151 | 132 | 35.73 | 32.72 | 30.26 | 17.67 | 16.38 |
| Book Value | -44.21 | -43.77 | -58.70 | -7.07 | 8.88 | -7.77 | -3.84 | 4.23 | 5.50 | -0.62 |
Company Profile
Company Details
| Full Name | Xtant Medical Holdings, Inc. |
| Country | United States |
| Employees | 141 |
| CEO | Sean E. Browne |
Stock Information
| Ticker Symbol | XTNT |
| Stock Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSEAMERICAN: XTNT |
Description
Xtant Medical Holdings develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DMB Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.